Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the completion of dosing in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410, a novel gene …
Ocugen Completes Dosing in Phase 1/2 Trial for Gene Therapy to Treat Geographic Atrophy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the progression of its OCU410ST GARDian clinical trial after the Data and Safety Monitoring Board (DSMB) approved moving forward with …
Ocugen Advances Stargardt Disease Therapy with Positive Clinical Trial Progress Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400, a gene therapy candidate for retinitis pigmentosa …
Ocugen Doses First Patient in Phase 3 Trial for Retinitis Pigmentosa Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a positive outcome from the Data and Safety Monitoring Board (DSMB) review of its Phase 1/2 ArMaDa clinical trial for OCU410, a …
Ocugen’s Gene Therapy Shows Promise in Early Trial for Age-Related Macular Degeneration Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced its upcoming inclusion in the Russell 3000® Index, set to take effect after the market closes on June 28, 2024. This announcement …
Ocugen to Join Russell 3000 Index Amid Transformative Year Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on innovative therapies, announced the completion of dosing in the second cohort of its groundbreaking GARDian clinical trial for …
Ocugen Advances with Phase 1/2 Trial for Stargardt Disease Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on gene therapies for eye diseases, reported its first-quarter financial results for 2024 and provided an update on its …
Ocugen Advances Gene Therapy Trials, Targets 2026 for Key Regulatory Approvals Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) recently revealed a novel approach to shareholder incentives by declaring a dividend of Series C Preferred Stock. For every share of common stock …
Ocugen Announces Unique Dividend Strategy with Series C Preferred Stock Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of a groundbreaking treatment for geographic atrophy (GA), an advanced form of dry age-related macular …
Ocugen Advances in Revolutionary Gene Therapy for Age-Related Macular Degeneration Read More MALVERN, PA — In a significant advancement for retinitis pigmentosa (RP) treatment, Ocugen, Inc. (NASDAQ: OCGN) has received favorable scientific advice from the European Medicines Agency (EMA) regarding its pivotal …
Ocugen’s Gene Therapy OCU400 Moves Closer to European Market with EMA’s Positive Opinion Read More